# Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium

- Source: PR Newswire M&A
- Published: 2026-11-02T12:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-two-abstracts-on-paxalisib-tumor-and-immune-reprogramming-research-accepted-for-poster-presentation-at-2026-san-antonio-breast-cancer-symposium-302925820.html
- Canonical: https://groundlevelnews.com/story/kazia-therapeutics-announces-two-abstracts-on-paxalisib-tumor-and-immu-2260d9/

Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov. 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._